PPH
·NASDAQ
--
--(--)
--
--(--)
Key Stats
Assets Under Management
1.19BUSD
Fund Flows (1Y)
482.10MUSD
Dividend Yield
1.89%
Discount/Premium to NAV
-0.07%
Shares Outstanding
11.64M
Expense Ratio
0.36%
About VanEck Pharmaceutical ETF
Issuer
Van Eck Associates Corporation
Brand
VanEck
Inception Date
Dec 20, 2011
Structure
Open-Ended Fund
Index Tracked
MVIS US Listed Pharmaceutical 25 Index
Management Style
Passive
Dividend Treatment
Distributes
Distribution Tax Treatment
Qualified dividends
Income Tax Type
Capital Gains
Max ST Capital Gains Rate
39.60%
Max LT Capital Gains Rate
20.00%
Primary Advisor
Van Eck Associates Corp.
Distributor
Van Eck Securities Corp.
PPH provides exposure to the largest, US-listed multinational pharmaceutical giants in the world. The fund holds just 25 securities, including big weights in household names. Like the underlying pharmaceutical market, PPH is top heavy and has to reweight its big holdings to accommodate RIC diversification requirements, capping a single issuer to 20%. Still, it captures the space well, even after excluding Asia entirely. Overall, PPH is a great option for investors seeking exposure to big, multinational pharma companies. The index is reviewed on a semi-annual basis.
Classification
Asset Class
Equity
Category
Sector
Focus
Health Care
Niche
Pharmaceuticals
Strategy
Vanilla
Geography
Developed Markets
Weighting Scheme
Market Cap
Selection Criteria
Market cap
Returns
1-Month | 3-Month | YTD | 1-Year | 3-Year | 5-Year | |
|---|---|---|---|---|---|---|
Price Performance | +2.83% | +15.37% | +17.91% | +17.11% | +32.77% | +55.87% |
NAV Total Return | +1.10% | +12.98% | +16.85% | +14.41% | +34.99% | +63.57% |
Ratings
No data is currently available
Ainvest’s AI-powered ETF Scoring Algorithm, built to help retail investors make smarter, data-driven decisions. Leveraging deep learning, reinforcement learning, and large language models, the algorithm scores ETFs across five key dimensions: Fund Flow, Momentum, Safety, Fundamentals, and Performance. Each factor is weighted by its correlation to future returns, resulting in a single, actionable score. Backtested over five years with consistently strong predictive accuracy. Ainvest brings institutional-grade artificial intelligence to everyday investors—transforming complexity into clarity with every score.
Holdings Analysis
Sector
Healthcare
100.00%
Healthcare
100.00%
Asset
Region
64.05%
31.4%
2.29%
2.26%
Category
Ratio
North America
64.05%
Europe
31.40%
Asia
2.29%
Africa/Middle East
2.26%
Investment Style
Mega
Large
Medium
Multi
Small
Value
Blend
Growth
Multi-Cap Blend
Provides exposure to companies of various sizes that exhibit both growth and value characteristics. This category offers a diversified portfolio with a mix of market caps.
Top 10 Holdings
Symbol
Ratio
LLY
Eli Lilly
24.26%
NVS
Novartis
9.14%
MRK
Merck
7.84%
NVO
Novo Nordisk
5.94%
GSK
GSK
4.75%
JNJ
Johnson & Johnson
4.73%
MCK
McKesson
4.52%
BMY
Bristol-Myers Squibb
4.49%
PFE
Pfizer
4.48%
AZN
Astrazeneca
4.40%
Top 10 Weight 74.55%
27 Total Holdings
Dividends
Dividend Payout History
Declaration Date | Record Date | Payment Date | Amount |
|---|---|---|---|
| 2025-10-01 | 2025-10-01 | 2025-10-06 | 0.393 |
| 2025-07-01 | 2025-07-01 | 2025-07-07 | 0.607 |
| 2025-04-01 | 2025-04-01 | 2025-04-04 | 0.524 |
| 2024-12-27 | 2024-12-27 | 2024-12-30 | 0.411 |
| 2024-10-01 | 2024-10-01 | 2024-10-04 | 0.409 |
| 2024-07-01 | 2024-07-01 | 2024-07-05 | 0.356 |
| 2024-04-01 | 2024-04-02 | 2024-04-05 | 0.533 |
Show more
Premium/Discount Chart
Premium/Discount to NAV
Price
1M
Assets Under Management
Assets Under Management
1M
Fund Flows
Inflows
Outflows
1M
